Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AUBE00 With Cetuximab in Solid Tumors
jRCT2031250094Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AUBE00 and cetuximab in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of AUBE00 plus cetuximab, Pharmacokinetics of AUBE00 (± cetuximab) and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
AUBE00cetuximab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250094.